Athens, Greece — GENESIS Pharma said it has expanded its commercial partnership with Alnylam Pharmaceuticals to include four Nordic markets: Denmark, Finland, Norway and Sweden.
The expanded agreement adds the Nordic region to GENESIS Pharma’s existing network of 13 Southeast European markets under its partnership with Alnylam, a RNAi therapeutics company.
Under the agreement, GENESIS Pharma will commercialize a portfolio of Alnylam RNAi therapeutics for serious cardiomyopathy conditions and rare genetic diseases across the expanded territory.
The partnership began in 2019 for Southeast Europe and has since grown to cover a broader portfolio and geographic footprint. The existing markets include Greece, Cyprus, Bulgaria, Romania, Slovenia, Croatia, Serbia, Bosnia and Herzegovina, Albania, the Republic of North Macedonia, Montenegro, Malta and Kosovo.
GENESIS Pharma said the latest expansion reflects both companies’ commitment to improving patient access to innovative therapies across Europe, particularly in regions with significant unmet medical needs.
“We are proud of our strong and established partnership with GENESIS Pharma and are delighted to broaden this across the Nordic region. Our commitment is to deliver transformational impact for patients across the world. By working alongside GENESIS Pharma, we can continue to address the needs of even more patients and their families, enabling them to benefit from Alnylam’s innovative RNAi therapeutics,” said Norton Oliveira, Senior Vice-President and Head of Partner and Emerging Markets at Alnylam Pharmaceuticals.
Constantinos Evripides, Managing Director of GENESIS Pharma, said the expansion marks a significant milestone for the partnership.
“Since 2019, we have been working closely with Alnylam to ensure patient access across Southeast Europe. The expansion in the Nordic countries marks a significant milestone in our partnership and reflects our ongoing efforts to strengthen our European footprint, building on our three-decade legacy and commitment to biotechnology. By combining Alnylam’s pioneering science with our strong regional expertise in bringing innovation closer to patients, we continue to expand our reach and enhance the value we deliver across healthcare systems. We are honored by the trust Alnylam has placed in our company and our people,” Evripides said.
